GZ 402666

Drug Profile

GZ 402666

Alternative Names: Avalglucosidase alfa; GZ-402666; neo rhGAA; Neo-recombinant human acid alpha-glucosidase; Neo-rhGAA; Neo-rhGAA enzyme therapy; NeoGAA

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Genzyme Corporation
  • Developer Sanofi Genzyme
  • Class Alpha-glucosidases
  • Mechanism of Action Alpha glucosidase replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Glycogen storage disease type II

Most Recent Events

  • 07 Feb 2018 Adverse events data from the phase II/III NEO-EXT trial in Glycogen storage disease type II released by Sanofi
  • 07 Feb 2018 Efficacy, adverse event and immunogenicity data from the phase I/II NEO 1 trial in Glycogen storage disease type II released by Sanofi
  • 07 Feb 2018 Sanofi announces intention to submit regulatory application for Glycogen storage disease type II in 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top